ReviewFrontiers in cell and developmental biology2020
Non-neuronal Role of Acetylcholinesterase in Bone Development and Degeneration.
Review in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Evidence for acetylcholinesterase as an early mediator in knee osteoarthritis: insights from synovial fluid analyses.Clinical rheumatology · 2026Article
- Cholinergic regulation of osteocyte mechanobiology: A paradigm for bone adaptation.Science advances · 2025Article
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis.Annals of medicine and surgery (2012) · 2024Review
- Proteome-wide Mendelian randomization provides novel insights into the pathogenesis and druggable targets of osteoporosis.Frontiers in medicine · 2024Article
- Bone-nerve crosstalk: a new state for neuralizing bone tissue engineering-A mini review.Frontiers in medicine · 2024Review
- Sex differences in the association between dietary choline intake and total bone mineral density among adolescents aged 12-19 in the United States.Frontiers in nutrition · 2024Article
- The therapeutic mechanism of Compound Lurong Jiangu Capsule for the treatment of cadmium-induced osteoporosis: network pharmacology and experimental verification.Frontiers in endocrinology · 2024Article
- Metabolomics study of osteopetrosis caused byFrontiers in endocrinology · 2024Article
- Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.Journal of cellular physiology · 2023Article
- The human acetylcholinesterase C-terminal T30 peptide activates neuronal growth through alpha 7 nicotinic acetylcholine receptors and the mTOR pathway.Scientific reports · 2023Article
- In Silico and In Vitro Methods in the Characterization of Beta-Carotene as Pharmaceutical Material via Acetylcholine Esterase Inhibitory Actions.Molecules (Basel, Switzerland) · 2023Article
- Effects of Donepezil on the Musculoskeletal System in Female Rats.International journal of molecular sciences · 2023Article
- Validation of Acetylcholinesterase Inhibition Machine Learning Models for Multiple Species.Chemical research in toxicology · 2023Article
- Interaction between the nervous and skeletal systems.Frontiers in cell and developmental biology · 2022Review
- Hemodynamic stress shapes subchondral bone in osteoarthritis: An emerging hypothesis.Journal of orthopaedic translation · 2022Review
- Article
- Roles for B[a]P and FICZ in subchondral bone metabolism and experimental temporomandibular joint osteoarthritis via the AhR/Cyp1a1 signaling axis.Scientific reports · 2021Article
- Article
- Untargeted Metabolomics Reveal the Protective Effect of Bone Marrow Mesenchymal Stem Cell Transplantation Against Ovariectomy-Induced Osteoporosis in Mice.Cell transplantationArticle
- Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives.International journal of immunopathology and pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetylcholinesterase (AChE), an enzyme catalyzing the degradation of acetylcholine, plays an important suppressive role in the cholinergic regulation by terminating the action of acetylcholine. The expression of acetylcholinesterase and other cholinergic components is not restricted to only brain and nerve tissues but can also be found in non-neuronal tissues like the immune system and bone tissue. Primary identification of these components has been achieved. However, the information about their specific functions and underlying molecular mechanisms in bone remains scattered. Here, the physiological process of bone development, homeostasis, and degeneration are introduced. Next, the cholinergic system and its expression in bone tissue is documented. Among them, special attention goes to AChE, as the structure of this enzyme suggests diverse binding affinities, enabled by a peripheral site and a catalytic site. The peripheral site supports the non-enzymatic function of AChE in non-neuronal systems. Based on recent studies, the non-neuronal roles of acetylcholinesterase, both enzymatically and non-enzymatically, in bone development, homeostasis and degeneration are summarized briefly together with potential mechanisms to support these functions. We conclude that AChE may be a potential therapeutic target for bone diseases like osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.